Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC By Ogkologos - May 19, 2026 49 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PLANeT study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL February 13, 2025 ASCO20 Virtual Research Round Up Podcast: Leukemia, Colorectal Cancer, and Lung... June 23, 2020 Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... June 13, 2019 EMA Recommends Granting a Marketing Authorisation for Generic Sunitinib December 18, 2020 Load more HOT NEWS Teen With Cancer On Dream Trip To NASA Gets Surprise Call... Death Rates from Lung Cancer will Fall Overall in the EU... ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma
